论文部分内容阅读
目的探讨不同降压药联合治疗方案的临床效果,并对其进行经济学评价。方法门诊需要联合用药治疗的原发性高血压患者随机分为3组:血管紧张素转换酶抑制剂(ACEI)+利尿剂(1组,洛汀新+双氢克尿噻,n=68)、钙拮抗剂(CCB)+β受体阻滞剂(2组,拜新同+倍他乐克,n=67)和ACEI+CCB(3组,洛汀新+拜新同,n=68)。观察血压达标率、治疗坚持率,并进行经济学评价(直接药费成本)。结果治疗6月后,3组联合治疗方案均能有效降低血压(血压达标率分别为1组:82.1%,2组:83.3%,3组:78.9%,P>0.05);3组治疗坚持率没有差异(1组:82.3%,2组:79.4%,3组:79.1%,P>0.05)。1组和2组平均每日直接药费远低于3组(1组:4.89元,2组:7.66元,3组:15.95元,P<0.05)。结论ACEI+利尿剂与CCB+β受体阻滞剂具有较好的经济学效益。
Objective To investigate the clinical effects of different antihypertensive drugs in combination therapy and evaluate their economics. Methods Outpatients were randomly divided into three groups: ACEI + diuretic (group 1, Lotensin + hydrochlorothiazide, n = 68) , CCB + β blockers (n = 2), ACEI + CCB (n = 67) ). Observe blood pressure compliance rate, treatment adherence rate, and economic evaluation (direct cost of medication). Results After 6 months of treatment, all the three combination regimens were effective in lowering blood pressure (blood pressure compliance rates were 1: 82.1%, 2: 83.3%, 3: 78.9%, P> 0.05) There was no difference (Group 1: 82.3%, Group 2: 79.4%, Group 3: 79.1%, P> 0.05). The average daily direct medical costs of group 1 and group 2 were much lower than those of group 3 (group 1: 4.89 yuan, group 2: 7.66 yuan, group 3: 15.95 yuan, P <0.05). Conclusion ACEI + diuretics and CCB + β blockers have good economic benefits.